Showing 2811-2820 of 3039 results for "".
- NIH Launches First U.S. Clinical Trial of Patient-Derived Stem Cell Therapy to Replace Dying Cells in Retinahttps://modernod.com/news/nih-launches-first-u-s-clinical-trial-of-patient-derived-stem-cell-therapy-to-replace-dying-cells-in-retina/2477175/Researchers at the National Eye Institute (NEI) are launching a clinical trial to test the safety of a novel patient-specific stem cell-based therapy to treat geographic atrophy, the advanced dry form of age-related macular degeneration (AMD). Geographic atrophy currently has no treatment.
- UK Regulator Unconditionally Clears Roche’s Purchase of Spark Therapeuticshttps://modernod.com/news/uk-regulator-unconditionally-clears-roches-purchase-of-spark-therapeutics/2477170/The UK Competition and Markets Authority (CMA) announced Monday the clearance of Roche’s proposed purchase of Spark Therapeutics after concluding that the deal would not negatively affect competition for haemophilia A treatments. The Swiss drugmaker noted that the offer period under the tra
- Stephen Hahn Confirmed as New FDA Chiefhttps://modernod.com/news/stephen-hahn-confirmed-as-new-fda-chief/2477168/The US Senate voted 72 to 18 on Thursday to confirm President Donald Trump nominee Stephen Hahn as the next FDA Commissioner. The radiation oncologist, who was recently cleared by the Senate Health, Education, Labor and Pensions Committee, replaces Scott Gottlieb, who stepped down in Ap
- SEED Acquires Majority Stake in Sensimedhttps://modernod.com/news/seed-acquires-majority-stake-in-sensimed/2477166/Sensimed announced the closure of a transaction whereby the Japanese public company SEED has acquired a majority stake in Sensimed. The transaction closed on November 29 with SEED now owning over 90% of outstanding sh
- Leiters and Prodigy Health Enter into National Sales and Marketing Agreementhttps://modernod.com/news/leiters-and-prodigy-health-enter-into-national-sales-and-marketing-agreement/2477157/Leiters and Prodigy Health have entered into a national sales and marketing agreement that will permit Prodigy Health to bring its ProdigyVision technology platform to the Leiters portfolio of 503B compounded sterile preparations in collaboration with the Leiters sal
- ImprimisRx’s FDA-Registered Outsourcing Facility Issued California Licensehttps://modernod.com/news/imprimisrxs-fda-registered-outsourcing-facility-issued-california-license/2477158/ImprimisRx announced that on December 9, 2019, its FDA-registered 503B outsourcing facility received a non-resident operating license and has now begun shipping into California. This license allows California-based ophthalmologists, optometrists, surgery centers and hospitals to order and stock I
- Quick Eye Test May Flag Unrecognized Brain Injuryhttps://modernod.com/news/quick-eye-test-may-flag-unrecognized-brain-injury/2477145/A quick, noninvasive, handheld device that detects changes in pupil size may offer rapid assessment of potential brain injury in young athletes who have sustained a high-impact hit to the head but who exhibit no obvious signs of brain injury, according to a
- Limelight Bio Emerges with $75 Million to Develop Next Generation Gene Therapieshttps://modernod.com/news/limelight-bio-emerges-with-75-million-to-develop-next-generation-gene-therapies/2477141/Limelight Bio, a privately held, multi-platform, multi-disease biopharmaceutical company developing novel gene therapies, raised $75 million in new financing funded by Apple Tree Partners (ATP), a life sciences innovation fund. Founded in 2017, Limelight Bio has developed proprietary technologies
- Positive Phase 3 Results for Genentech’s Satralizumab in Neuromyelitis Optica Spectrum Disorder Published in NEJMhttps://modernod.com/news/positive-phase-3-results-for-genentechs-satralizumab-in-neuromyelitis-optica-spectrum-disorder-published-in-nejm/2477130/Genentech announced that data from SAkuraSky, a pivotal phase 3 study of the investigational medicine satralizumab for the treatment of neuromyelitis optica spectrum disorder (NMOSD), were published in the November 27, 2019 online issue of the New England Journal of Medicine (NEJM).
- AI Screening for Diabetic Retinopathy Moves to Retail Clinicshttps://modernod.com/news/ai-screening-for-diabetic-retinopathy-moves-to-retail-clinics/2477127/Retail health clinics have been part of the trend in making healthcare more convenient, and now another option is being offered—testing for diabetic retinopathy—according to a Medscape report. However, an ophthalmologist won’